§ Mrs. Iris RobinsonTo ask the Secretary of State for Health (1) what percentage of breast cancer patients diagnosed in the past 12 months received treatment with Trastuzumab; [176867]
(2) what percentage of patients diagnosed with breast cancer were tested for HER2 in the last year for which figures are available. [176868]
§ Miss Melanie JohnsonThe Department does not collect information on the percentage of breast cancer patients who receive treatment with Herceptin or who are tested for human epidermal growth factor receptor 2.
Professor Mike Richards, National Cancer Director, has been asked to investigate the variation in uptake of the National Institute for Clinical Excellence approved chemotherapy drugs, including Herceptin. His report is due to be published shortly.